Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Executive Summary
Center for Drug Evaluation and Research Director Janet Woodcock continues to promote innovation in clinical trial design with a review of master protocols in the New England Journal of Medicine.
You may also be interested in...
How Can US FDA Bolster Drug Development? The Agency Wants Your Advice
Public meeting scheduled for November to seek recommendations for policies that FDA could implement short-term to promote drug development programs.
Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda
US FDA plans new guidances on real-world data, clinical trial statistics, and patient input in coming this year.
New Acting US FDA Commissioner Shares Agency's Clinical Trial Reform Message
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
